Halofuginone | 卤夫酮 | RU-19110 | Prolyl-tRNA Synthetase Inhibitor

首页 / / / / Halofuginone

常山酮 /Halofuginone {[allProObj[0].p_purity_real_show]}

货号：A162412 同义名： 卤夫酮 / RU-19110

Halofuginone is an inhibitor of prolyl-tRNA synthetase with Ki of 18.3 nM.It could also down-regulate Smad3 and blocked TGF-β signaling at 10 ng/mL in mammal.

Halofuginone 化学结构
CAS号：55837-20-2

Halofuginone 3D分子结构
CAS号：55837-20-2

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Halofuginone 纯度/质量文件产品仅供科研

货号：A162412 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

DNA 亚型比较

产品名称	DNA synthesis ↓ ↑	helicase ↓ ↑	RdRp ↓ ↑	ribonucleotide reductase ↓ ↑	tRNA synthetase ↓ ↑	YB-1 ↓ ↑	其他靶点	纯度
Fexinidazole	✔							98%
Daptomycin	✔							98%
Blasticidin S·HCl	✔							98%
Metronidazole	✔							98%
Daunorubicin HCl	+++ DNA synthesis, Ki: 20 nM							98%
Triglycidyl isocyanurate	✔						p53	98+%
Nedaplatin	✔							99%+
Bendamustine	✔							98+%
Trifluridine	✔							98%
Robinetin	✔							99%+
Carboplatin	✔							99%
Cidofovir	✔							99%
Cisplatin	✔							99%
Cytarabine	++++ DNA synthesis, IC50: 16 nM							98%
Acelarin	++++ DNA synthesis, EC50: 0.2 nM							99%+
Oxaliplatin	✔							98%
YK-4-279		✔						99%+
ML216		+ BLM^636-1298, IC50: 0.97 μM BLM^full-length, IC50: 2.98 μM						99%+
RK-33		✔						98%
Brr2-IN-3		✔						99%+
Phen-DC3 Trifluoromethanesulfonate		✔						98%
Favipiravir			✔					97%
Suramin sodium salt			++ RdRp, IC50: 0.26 μM					99%+
Clofarabine				++ Ribonucleotide reductase, IC50: 65 nM				97%
Didox				✔				98%
(E)-3-AP				✔				97%
Halofuginone					+++ prolyl-tRNA synthetase, Ki: 18.3nM			99%+
BC-LI-0186					+++ Leucyl-tRNA synthetase, Kd: 42.1 nM Leucyl-tRNA synthetase, IC50: 46.11 nM			98%
SU056						+ YB-1, IC50: 1.73 μM		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Halofuginone 生物活性

靶点	tRNA synthetase prolyl-tRNA synthetase, Ki:18.3nM
描述	Halofuginone is the competitively inhibitor of prolyl-tRNA synthetase with Ki of 18.3 nM.It could also down-regulate Smad3 and blocked TGF-β signaling at 10 ng/mL in mammal.

Halofuginone 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01978366	Duchenne Muscular Dystrophy	Phase 2	Terminated(Dosing stopped)	-	United States, California ... 展开 >> University of California, Davis Medical Center Sacramento, California, United States, 95817 United States, Maryland Kennedy Krieger Institute, Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21205 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 收起 <<
NCT01847573	Duchenne Muscular Dystrophy	Phase 1 Phase 2	Terminated(Dosing stopped)	-	United States, California ... 展开 >> University of California, Davis Medical Center Sacramento, California, United States, 95817 United States, Maryland Kennedy Krieger Institute, Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21205 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 收起 <<
NCT02525302	Duchenne Muscular Dystrophy	Phase 2	Terminated(Dosing stopped)	-	United States, California ... 展开 >> University of California, Davis Medical Center Sacramento, California, United States, 95817 United States, Maryland Kennedy Krieger Institute, Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21205 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 收起 <<

Halofuginone 参考文献

[1]Nelson EF, Huang CW, et al. Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts. Mol Vis. 2012;18:479-87.

[2]Keller TL, Zocco D, et al. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol. 2012 Feb 12;8(3):311-7.

Halofuginone 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.41mL

0.48mL

0.24mL

12.06mL

2.41mL

1.21mL

24.11mL

4.82mL

2.41mL

Halofuginone 技术信息

CAS号	55837-20-2
分子式	C₁₆H₁₇BrClN₃O₃
分子量	414.682

别名	卤夫酮 ;RU-19110
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Sealed in dry,Room Temperature

溶解度

DMSO: 18 mg/mL(43.41 mM)，配合低频超声，并调节pH至5，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01978366	Duchenne Muscular Dystrophy	Phase 2	Terminated(Dosing stopped)	-	United States, California ... 展开 >> University of California, Davis Medical Center Sacramento, California, United States, 95817 United States, Maryland Kennedy Krieger Institute, Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21205 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 收起 <<
NCT01847573	Duchenne Muscular Dystrophy	Phase 1 Phase 2	Terminated(Dosing stopped)	-	United States, California ... 展开 >> University of California, Davis Medical Center Sacramento, California, United States, 95817 United States, Maryland Kennedy Krieger Institute, Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21205 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 收起 <<
NCT02525302	Duchenne Muscular Dystrophy	Phase 2	Terminated(Dosing stopped)	-	United States, California ... 展开 >> University of California, Davis Medical Center Sacramento, California, United States, 95817 United States, Maryland Kennedy Krieger Institute, Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21205 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 收起 <<
NCT00027677	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	Belgium ... 展开 >> U.Z. Gasthuisberg Leuven, Belgium, B-3000 Netherlands University Hospital - Rotterdam Dijkzigt Rotterdam, Netherlands, 3000 CA Daniel Den Hoed Cancer Center at Erasmus Medical Center Rotterdam, Netherlands, 3008 AE 收起 <<
NCT00064142	AIDS-related Kaposi Sarcoma ... 展开 >> Recurrent Kaposi Sarcoma 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> AIDS - Associated Malignancies Clinical Trials Consortium Rockville, Maryland, United States, 20850 收起 <<

常山酮 /Halofuginone {[allProObj[0].p_purity_real_show]}

Halofuginone 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Halofuginone 质控信息

Halofuginone 生物活性

Halofuginone 临床研究

Halofuginone 参考文献

Halofuginone 实验方案

Halofuginone 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

常山酮 /Halofuginone {[allProObj[0].p_purity_real_show]}

Halofuginone 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Halofuginone 质控信息

Halofuginone 生物活性

Halofuginone 临床研究

Halofuginone 参考文献

Halofuginone 实验方案

Halofuginone 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Halofuginone 纯度/质量文件产品仅供科研